We raised high-titre antisera to two LSD-bovine serum albumin conjugates, one iinked via the indole nitrogen, the other via the amide side-chain. The antisera were specific for different parts of the LSD molecule, as demonstrated by cross-reactivity studies with LSD, its metabolites, ergot alkaloids, and closely related compounds. The antisera were used to develop a double-antibody radioimmunoassay with a detection limit of about 0.4 g of LSD per liter of unextracted urine or serum. We saw no nonspecific interference by urine, serum, or from a series of commonly used drugs. There was good correlation between immunoassay values obtained with the two antisera (r = 0.91). However, the antiserum linked via the indole nitrogen gave consistently higher results for sampies from persons who had taken LSD, owing to greater cross-reactivity with LSD metabolites. Radioimmunoassay by use of two such antisera is a more specific screening procedure for LSD abuse than has been available previously. In addition, antisera cross-reacting with LSD metabolites allow measurement of these compounds, for which there is no satisfactory method at the concentrations found in biological fluids in man.
C. Moffat,2 John G. Ratcliffe,1 tension of this method involves high-pressure liquid chromatography, monitored by fluorescence, with subsequent thin-layer chromatography of the appropriate fraction of the eluate (5) . This technique eliminates the problem of nonspecific interference but still requires a large sample of urine or plasma. Both methods are technically demanding and are unsuited for assaying large numbers of samples. For this reason several groups have developed radioimmunoassays (RIA) for LSD that offer potential advantages of sensitivity, small sample-volume requirement, and large sample capacity.
Antisera for RIA have been produced by using conjugates prepared from lysergic acid and poly-L-lysine (6) or human serum albumin (7) . In both cases, linkage was via the lysergic acid carboxyl group directly to a protein -NH2 group. These antisera exhibited poor specificity for LSD and cross-reacted strongly with other ergot alkaloids. Two other groups used conjugates of LSD and either bovine serum albumin (8) or human serum albumin (9) , in which the protein was linked to the indole nitrogen atom by a Mannich condensation reaction. These conjugates produced antisera of much greater specificity than did the lysergic acid conjugates.
In this study, we raised antisera to a new conjugate of LSD in which an ethyl group was substituted by a four-carbon spacer chain coupled to bovine serum albumin. Thus the hapten was the pharmacologically active isomer of LSD, differing from LSD only in the substitution of one hydrogen atom. Antisera were also raised to a LSD-bovine serum albumin conjugate prepared by Mannich condensation.
By using antisera specific for differing parts of the LSD molecule we hoped to identify those structurally related compounds and metabolites of LSD likely to cross-react in the radioiminunoassay.
A full evaluation of the sensitivity and specificity of each antiserum in a double-antibody RIA is presented and concentrations and stability of LSD-like activity in human serum and urine are reported.
Structural formulas for LSD and some related compounds are shown in Figure 1 . 
Materials and Methods

Reagents
LSD standard and tracer.
[2(n)-3H]Lysergic acid diethylamide (specific activity, 49 Ci/g) was obtained from the Radiochemical Centre, Arnersham, U. K. This material undergoes gradual radiolysis in aqueous solution at a rate of about 5% per month. Storage in the form in which it is supplied ensures minimal decomposition. Unlabeled LSD tartrate was generously provided by Sandoz Products Ltd., Feltham, Middlesex TW13 4EP, U.K.
Preparation of conjugate
I. The method of Taunton-Rigby et al. (8) was closely followed, although the resulting conjugate was largely insoluble and the LSD/serum albumin ratio could not be quantitatively determined from the ultraviolet absorption at 310 nm.
Antiserum
I. Five New Zealand White rabbits were immunized by subcutaneous and intramuscular routes with 1 mg of conjugate I in an emulsion of physiological saline and complete Freund's adjuvant (1/2 by vol). Subsequent booster injections (0.1 mg of conjugate, emulsified as described) were given at monthly intervals, and after four months all five rabbits had produced antiserum to LSD usable at final dilutions of 5000 or 10 000 under the conditions of the assay. A solution of the mixed anhydride (1 mmol) of sulfuric and lysergic acids in dimethyiformamide (10 ml) was prepared by the method of Garbrecht (10) . To this mixture, kept at 0#{176}C, was added ethyl 6-ethylaminohexanoate (5 mmol). After 20 mm, 10 ml of saturated aqueous sodium chloride solution was added and the resulting mixture was extracted five times with 20-ml portions of dichloromethane. These extracts were dried over anhydrous MgSO4 and evaporated under reduced pressure to give an oil, which was chromatographed on a column containing neutral alumina. After removing the dimethylformamide from the column with dichloromethane, two bands containing material that fluoresced under ultraviolet light (254 nm) could be eluted with ethanol/dichloromethane (1/4) and ethanol/dichloro. methane (1/1). The infrared spectrum of each of these fractions contained bands for amide (1640 cm-1) and ester (1720 cm-'). The fractions were combined and dissolved in 10 ml of a mixture of equal volumes of methanol and sodium hydroxide (1 mol/liter) and kept at 60 #{176}C, under nitrogen, for an hour. After cooling, the solution was saturated with sodium chloride, brought to pH 6.5, and extracted three times with 10-mi portions of t -amyl alcohol. The extracts were evaporated at 40-50 #{176}C under reduced pressure (13.3 Pa) This hapten (30 mg) was conjugated to bovine serum albumin (300 mg) (Sigma Chemical Co., Kingstonupon-Thames, KT2 7BH, U. K.) by using isobutylchloroformate according to the method of Wainer et al. (11) . The degree of substitution was determined by dialyzing the reaction mixture against five changes of pH 7.0 phosphate buffer at 4 #{176}C and measuring the quantity of the hapten present in the dialysate by ultraviolet absorption and spectrophotofluorometry. We estimated that between 12 and 15 hapten molecules were conjugated per molecule of bovine serum albumin. In radioimmunoassays employing antiserum I, the bound fraction was precipitated by donkey anti-rabbit precipitating serum (RD17, Wellcome Reagents Ltd., Beckenham, U. K.) with non-immune rabbit serum as a carrier. Rabbit anti-goat precipitating serum (RD39, Weilcome Reagents Ltd.) and non-immune sheep serum were used to precipitate the antibody-bound fraction of antiserum II. The conditions described for the precipitation of the antibody-bound fraction (see Assay Procedure)
were determined experimentally and represent the concentrations of second antibody and carrier serum giving maximum precipitation of the bound fraction. 
L-LSD
The assay tubes were incubated for 3 h at room temperature, then centrifuged at 2000 X g for 30 mm to precipitate the antibody-bound fraction. The supernates were decanted into disposable counting vials and 10 ml of scintillation fluid (NE 260; Nuclear Enterprises Ltd., Edinburgh EH 11 4EY, U. K.) was added to each. The vials were counted in a beta-counter to accumulate 10 000 counts in the vials containing the total tracer added to the assay (about 5 mm).
Specimens
Samples of urine, serum, or stomach washings were obtained from people suspected by the police of ingesting LSD. Neither the dose nor the time of ingestion were known. Control urines and sera were obtained from 50 subjects (hospital patients and laboratory staff) known not to have taken LSD. The relative cross-reactivities of a large number of compounds with the two LSD antisera were studied. The dose-response curves of these compounds, usually in the range 1-500 jig/tube, were compared with that of LSD. Cross reactivities reported are the amounts of each compound producing 50% inhibition of the binding achieved in the presence of zero concentration of LSD. (Table  2) . Antiserum II: Cross-reactivity studies with this antiserum are reported in Tables 1 and 2 and Figure 3 . Lysergic acid monoethylamide, D-lysergamide, lumi-LSD, D-lysergic acid, iso-lysergic acid, ergometrine, and methylergometrine gave significant inhibition of binding, and in all cases their inhibition curves approximately paralleled that of LSD. Scatchard plots of data from standard curves (12) yielded apparent equilibrium constants for antisera I and II of 1.9 X 1010 and 3.6 X 10 liter/mol, respectively.
Results
Characterization of Antisera
Standard Curve
Curves for inhibition of LSD (Figure 4 ) covered the ranges of about 0.4-10 big/liter (antiserum I) and 0.4-40 gig/liter (antiserum II). We arbitrarily defined the limit of detection as that LSD concentration producing 95% of the specific binding achieved at zero LSD concentration. Nonspecific binding was 2-5% of the total counts added. The addition of 25 d of LSD-free buffer, serum, or urine as unknown had no effect on the sensitivity, specific binding, or shape of the standard curve. Volumes of serum or urine exceeding 25 Ll slightly decreased the percentage of total counts bound, but did not alter the shape of the curve. This depression in specific binding was attributable to nonspecific interference in the formation of the immune complex and not to quenching at the scintillation counting stage. With both antisera, LSD-positive specimens of urine and serum, on dilution, gave inhibition curves that paralleled their respective LSD inhibition curves, indicating that the assays measure LSD or closely related metabolites, or both.
Urine samples from cases 4, 6, 7 and 9 (Table 4) were also extracted with heptane/isoamylalcohol (98/2) and then back extracted into 0.1 mol/liter hydrochloric acid. The extract was analyzed by high-pressure liquid chromatography with fluorescence detection, and a peak with the same retention volume as LSD was obtained in each case. The concentrations detected in this way were 30-40% of those obtained by radioimmunoassay with antiserum II. The positive stomach washing (case 13) was also analyzed by this method and gave a value of 5 ig of LSD per liter.
Precision and Recovery
Urine and serum containing known concentrations of LSD (2.5 and 0.59 /Lg/liter) were assayed in replicate 10 times with antiserum I to determine within-batch variation. The precision of the assay and the analytical recovery of LSD are reported in Table 3 .
Results of LSD Radioimmunoassay
All specimens from control subjects (50 urines and 50 sera) assayed undiluted and diluted 10-fold in diluent buffer contained no LSD by radioimmunoassay-i.e., values less than the arbitrary detection limit of 0.4 gig/liter (see Figure 4) . Urines from two patients with proteinuria
(1 and 2 g of protein per 24 h) also showed no detectable LSD. LSD-like activity in suspected LSD-positive urine was higher with antiserum I than with antiserum II (Table 4) . Values for [SD determined by radioimmunoassay with antiserum 1(x) and antisera 11(y) correlated well (y = 0.54x + 0.8; r = 0.91).
Stability of LSD in Biological Fluids
Diluent buffer, pooled human serum, pooled urine, and whole blood (heparinized) containing LSD (3.9 iig/liter) were allowed to stand at ambient temperature for six days in a room lit by fluorescent tubes. [SD was assayed with antiserum I. After three days, LSD-like activity in whole blood had decreased progressively to 70% of the initial level, whereas in diluent buffer, urine, and serum, 80% of the initial concentration remained after six days. This contrasts markedly with a finding that the LSD concentration in buffer, as measured by fluorescence, declined to 25% of the original value after seven days at room temperature in daylight (P. J. Twitchett; personal communication). The apparent stability of LSD at ambient temperature under fluorescent lighting, as determined by RIA, may be explained by cross-reaction of lumi-LSD with antiserum I.
Discussion
We raised antisera of high titre and affinity by using two different conjugates in which LSD was coupled to bovine serum albumin either through the indole nitrogen atom (antiserum I) or though an ethyl substituent by means of a four-carbon spacer chain (antiserum II). In cross-reactivity studies with a number of LSD metabolites and structurally related compounds, the two antisera gave markedly differing patterns of specificity, reflecting the position of coupling of the hapten.
Antiserum I had a similar specificity to that described by Taunton-Rigby et al. (8) , prepared by use of the same conjugate.
Both appeared to be highly specific for structures retaining the LSD side-chain, and also part of rings C and D, although our antiserum was much less reactive with the L-isomer of LSD. These authors did not report an equilibrium constant for their antiserum, although in practice the sensitivity of their radioimmunoassay was similar to that reported here. The antiserum produced by Castro et a!. (9) was not tested for cross-reactivity with ergot alkaloids or other related compounds.
In contrast with the antisera produced by Van Vunakis et al. (6) and by Loeffler and Pierce (7), who used a lysergic acid conjugate linked via the carboxyl group, our antiserum II cross-reacted minimally with ergot alkaloids such as ergonovine and ergotamine that have large substituent groups on carbon 8. The greatly improved specificity of antiserum ii is probably due to the fact that the hapten differs from LSD only in the substitution of one hydrogen atom while being separated from the protein by four carbon atoms. Antiserum II showed greater specificity for the four rings than did antiserum I, although slightly poorer specificity in the region of the side chain.
LSD is reported to be rapidly and almost completely metabolized in several species, including man (2, 13, 14) , and most of the metabolites are excreted in the urine. Metabolites identified in experimental animals include 13-hydroxy-LSD, 14-hydroxy-LSD, their glucuronides, and 2-oxo-LSD (2, 13) , and from the known specificity of our antisera it seems likely that these metabolites may contribute significantly to the values for LSD as determined by RIA. In general, urines obtained after LSD ingestion gave greater inhibition of binding with antiserum I than with antiserum II, possibly reflecting the presence of metabolites of LSD possessing structural modifications close to the indole nitrogen, such as 2-oxo-LSD, and the 13-and 14-hydroxy metabolites or their glucuronides. In the case of the stomach wash and sera, [SD-like activity determined with the two antisera were generally in good agreement, which may reflect the absence or low concentrations of metabolites in these fluids.
In screening for LSD abuse, an RIA with an antiserum of type I specificity has the advantage that it may detect a wider range of metabolites than an antiserum of type II. However, antiserum II may give results that more closely reflect the concentration of unmetabolized [SD present, and consequently may be more suited for use in pharmacological research. A major advantage of RIA over spectrophotofluorometric methods is that the latter cannot distinguish between LSD and many of the ergot alkaloids, because they have the same excitation and emission spectra. By RIA, with use of antiserum I in combination with a type II antiserum, the possibility of falsely positive values owing to interference by ergot alkaloids can be confidently excluded. A further advantage is that RIA detects LSD metabolites that are not extracted by the methods used to extract LSD for assay by high-pressure liquid chromatography or fluorometry. This may be of great importance where samples are taken a day or more after ingestion, when the serum or urine LSD concentration has dropped below the limit of detection by other techniques. Thus, RIA may offer the possibility of detecting LSD longer after a dose than the other methods mentioned.
Interpretation of the significance of immunoreactive LSD concentrations with respect to probable dosage or time since ingestion, and the correlation of values with biological activity, must await controlled experiments in man. Up to the present, however, ethical considerations have prevented us doing such experiments.
In conclusion, the assays we report in this study detect approximately 10 pg of LSD in 25 il of urine or serum and in practice have been found to be rapid, reproducible, and require only 50 l of biological fluid for duplicate determinations.
Under the conditions stated, nonspecific interference from substances in urine and serum, which has been a problem with an earlier assay (8) , was not apparent.
